Get 40% Off
🚨 Volatile Markets? Find Hidden Gems for Serious Outperformance
Find Stocks Now

Abcam signs licensing deal with Roche; shares rise

Published 22/01/2018, 09:06
© Reuters.  Abcam signs licensing deal with Roche; shares rise

(Reuters) - British biotechnology firm Abcam Plc (L:ABCA) said on Monday it signed a deal with Roche Holding AG (S:ROG) to get rights to a portfolio of the Swiss drugmaker's research products in its life science division.

The Cambridge-based antibody maker said it would obtain the exclusive rights to brand and market a portfolio of 760 products that are for research use only (RUO) from Roche's U.S.-based unit Spring Bioscience Corp.

Roche will retain the antibody development capabilities and rights pertaining to the Spring Portfolio for internal research, companion diagnostic and IVD uses.

Abcam said it was also granted RUO rights for all future products developed by Spring that Roche requests to be commercialised for an initial period of 10 years.

Shares of Abcam were up about 1.2 percent at 0851 GMT (9.51 a.m. BST).

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.